Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16938669 | 1.00 | HTR2A (0.60) | HTR2APARP1MEN1CYP3A4CYP2D6 | |
| SCHEMBL3670524 | 1.00 | HTR2A (0.60) | HTR2APARP1MEN1CYP3A4CYP2D6 | |
| SCHEMBL29383346 | 1.00 | HTR2A (0.60) | HTR2APARP1MEN1CYP3A4CYP2D6 | |
| SCHEMBL22953388 | 0.85 | HTR2A (0.43) | HTR2APARP1MEN1CYP3A4CYP2D6 | |
| SCHEMBL22952986 | 0.82 | PARP1 (0.46) | HTR2APARP1CYP3A4DRD2DRD1 | |
| SCHEMBL22953390 | 0.76 | HTR2A (0.36) | HTR2APARP1DRD2DRD1KIF11 | |
| Hydrochloric Acid SCHEMBL29960806 | 0.74 | HTR2A (0.97) | HTR2AMEN1CYP3A4CYP2D6KMT2A | |
| SCHEMBL6345215 | 0.74 | HTR2A (0.46) | HTR2APARP1MEN1CYP3A4CYP2D6 | |
| SCHEMBL29383649 | 0.74 | HTR2A (0.46) | HTR2APARP1MEN1CYP3A4CYP2D6 | |
| SCHEMBL22952989 | 0.73 | PARP1 (0.43) | HTR2APARP1CYP3A4KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414457-B1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2007-06-20 | — | — | EP | claimed |
| US-7091212-B2 | Chiral dinapsoline | PURDUE RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | claimed |
| US-20040063741-A1 | Chiral dinapsoline | SIT SING-YUEN (US) | 2004-04-01 | — | — | US | claimed |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1414457-B1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1414457-B1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2007-06-20 | — | — | EP | disclosed |
| US-7091212-B2 | Chiral dinapsoline | PURDUE RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-7091212-B2 | Chiral dinapsoline | PURDUE RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1414457-A4 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1414457-A1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040063741-A1 | Chiral dinapsoline | SIT SING-YUEN (US) | 2004-04-01 | — | — | US | disclosed |
| US-20040063741-A1 | Chiral dinapsoline | SIT SING-YUEN (US) | 2004-04-01 | — | — | US | disclosed |
| WO-2003013532-A1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | HTR2A 17/4885PARP1 2956/4885MEN1 3906/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | HTR2A 51/4885PARP1 2962/4885MEN1 4494/4885 |
| US-20040063741-A1 | Chiral dinapsoline | NAP1L1, DDAH1, NAP1L4 | HTR2A 49/4885PARP1 967/4885MEN1 2071/4885 |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DRD2, DRD1, DRD3 | HTR2A 17/4885PARP1 2944/4885MEN1 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.